UY32417A - Compuestos de piridazinona - Google Patents

Compuestos de piridazinona

Info

Publication number
UY32417A
UY32417A UY0001032417A UY32417A UY32417A UY 32417 A UY32417 A UY 32417A UY 0001032417 A UY0001032417 A UY 0001032417A UY 32417 A UY32417 A UY 32417A UY 32417 A UY32417 A UY 32417A
Authority
UY
Uruguay
Prior art keywords
ring
piridazinona
compounds
substituent
substituted
Prior art date
Application number
UY0001032417A
Other languages
English (en)
Inventor
Taniguchi Takahiko
Kawada Akira
Kondo Mitsuyo
John F Quinn
Kunitomo Jun
Yoshikawa Masato
Fushimi Makoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY32417A publication Critical patent/UY32417A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención provee un compuesto que tiene el efecto de inhibir la PDE inhibition, y que es útil como un medicamento para prevenir o tratar la esquizofrenia o etc. Un compuesto de la formula I donde R1 representa a sustituyente, R2 representa a un átomo de hidrogeno, o un sustituyente. El anillo A representa un anillo aromático que puede estar sustituido, El Anillo B representa un anillo heteroaromatico de 5 miembros que puede estar sustituido o una sal del mismo.
UY0001032417A 2009-02-05 2010-02-04 Compuestos de piridazinona UY32417A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20220709P 2009-02-05 2009-02-05
US21392709P 2009-07-30 2009-07-30

Publications (1)

Publication Number Publication Date
UY32417A true UY32417A (es) 2010-08-31

Family

ID=42398214

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032417A UY32417A (es) 2009-02-05 2010-02-04 Compuestos de piridazinona

Country Status (38)

Country Link
US (7) US8916566B2 (es)
EP (2) EP3006031A1 (es)
JP (1) JP5659166B2 (es)
KR (1) KR101730665B1 (es)
CN (1) CN102365020B (es)
AR (1) AR075238A1 (es)
AU (1) AU2010211050B2 (es)
BR (1) BRPI1008498B8 (es)
CA (1) CA2751565C (es)
CO (1) CO6410258A2 (es)
CR (1) CR20110440A (es)
DK (1) DK2393360T3 (es)
DO (1) DOP2011000254A (es)
EA (1) EA020690B1 (es)
EC (1) ECSP11011305A (es)
ES (1) ES2561181T3 (es)
GE (1) GEP20146004B (es)
HK (1) HK1164642A1 (es)
HR (1) HRP20160065T1 (es)
HU (1) HUE027478T2 (es)
IL (1) IL214137A (es)
JO (1) JO3114B1 (es)
MA (1) MA33072B1 (es)
ME (1) ME02337B (es)
MX (1) MX2011008305A (es)
MY (1) MY170610A (es)
NZ (1) NZ594851A (es)
PE (1) PE20110991A1 (es)
PL (1) PL2393360T3 (es)
RS (1) RS54504B1 (es)
SG (1) SG173175A1 (es)
SI (1) SI2393360T1 (es)
SM (1) SMT201600008B (es)
TN (1) TN2011000362A1 (es)
TW (1) TWI457333B (es)
UY (1) UY32417A (es)
WO (1) WO2010090737A1 (es)
ZA (1) ZA201106074B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
ES2567283T3 (es) 2008-06-03 2016-04-21 Intermune, Inc. Compuestos y métodos para tratar trastornos inflamatorios y fibróticos
AU2010211050B2 (en) 2009-02-05 2016-05-12 Takeda Pharmaceutical Company Limited Pyridazinone compounds
PE20130346A1 (es) 2010-06-24 2013-03-30 Takeda Pharmaceutical Compuestos heterociclicos fusionados
EP2593107A1 (en) * 2010-07-12 2013-05-22 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
JP5785548B2 (ja) 2010-08-04 2015-09-30 武田薬品工業株式会社 縮合複素環化合物
WO2012018059A1 (ja) 2010-08-04 2012-02-09 武田薬品工業株式会社 複素環化合物
EP2601192B1 (en) 2010-08-04 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
JP5800814B2 (ja) * 2010-08-10 2015-10-28 武田薬品工業株式会社 複素環化合物およびその用途
JP2013234123A (ja) * 2010-09-03 2013-11-21 Taisho Pharmaceutical Co Ltd ３−ピラゾリル−２−ピリドン誘導体
KR20140009372A (ko) 2011-02-18 2014-01-22 알러간, 인코포레이티드 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체
US9029388B2 (en) 2011-03-16 2015-05-12 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
JP6153513B2 (ja) * 2011-08-22 2017-06-28 武田薬品工業株式会社 哺乳類中のホスホジエステラーゼ（ｐｄｅ１０ａ）を定量的に画像化する放射性トレーサとしての放射標識された化合物及びその用途
WO2013073577A1 (ja) 2011-11-15 2013-05-23 アステラス製薬株式会社 ジヒドロキシ芳香族へテロ環化合物
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
BR112015019942A2 (pt) * 2013-02-21 2017-07-18 Takeda Pharmaceuticals Co método para produzir um composto, e, composto
JPWO2014142322A1 (ja) 2013-03-15 2017-02-16 第一三共株式会社 ベンゾチオフェン誘導体
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
KR102286860B1 (ko) * 2013-09-12 2021-08-05 얀센 바이오파마, 인코퍼레이트. 피리다지논 화합물 및 이의 용도
UA121199C2 (uk) 2013-09-12 2020-04-27 Аліос Біофарма, Інк. Азапіридонові сполуки та їх застосування
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
ES2544869B2 (es) * 2014-03-04 2016-01-18 Universidade De Vigo Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
EP3120871B1 (en) * 2014-03-18 2023-06-28 Takeda Pharmaceutical Company Limited Solid dispersion
EP3126362B1 (en) 2014-04-02 2022-01-12 Intermune, Inc. Anti-fibrotic pyridinones
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
EA036776B1 (ru) 2015-03-11 2020-12-21 Янссен Байофарма, Инк. Соединения азапиридона и способы их применения
WO2016191935A1 (en) * 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
BR112018011817A2 (pt) 2015-12-22 2018-12-04 Jiangsu Hengrui Medicine Co derivado de benzopiperidina, método de preparação do mesmo, e uso médico do mesmo
WO2019161179A1 (en) 2018-02-15 2019-08-22 Ovid Therapeutics Inc. Methods of treating developmental syndromes with pde10a inhibitors
CN108498868B (zh) * 2018-04-03 2020-09-15 北京大学口腔医学院 具有细胞外基质电学拓扑特征的带电复合膜及其制备方法
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
WO2019241787A1 (en) * 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
US20210379061A1 (en) * 2018-09-28 2021-12-09 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders
MX2019008440A (es) 2019-07-15 2021-01-18 Dva Farma Mexicana S A De C V Composiciones de recubrimientos en pelicula para tabletas con brillantez incrementada, procedimiento de preparacion y aplicacion.
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011693A1 (de) * 1978-10-03 1980-06-11 Ciba-Geigy Ag Neue N-(trifluormethansulfonylaminophenyl)-substituierte N-Heterocyclen, ihre Herstellung, sie enthaltende Mittel und ihre Verwendung zur Beeinflussung des Pflanzenwachstums
FR2648135B1 (fr) * 1989-06-07 1991-09-27 Pf Medicament Derives de phenyl-1-dihydro-1,4 amino-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
EP1130015A4 (en) 1998-08-14 2006-02-08 Nihon Nohyaku Co Ltd PYRIDAZINONE DERIVATIVES
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
ATE326458T1 (de) 2000-09-15 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
WO2005120514A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
AU2005323794B2 (en) 2005-01-07 2012-07-19 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as PDE10 inhibitors
US7763617B2 (en) * 2005-03-07 2010-07-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient
JP2009541481A (ja) 2006-06-26 2009-11-26 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての三環式ヘテロアリール化合物
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
AR074343A1 (es) 2008-11-14 2011-01-12 Amgen Inc Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10
ES2401670T3 (es) * 2008-12-04 2013-04-23 F. Hoffmann-La Roche Ag Derivados de piridazinona
AU2010211050B2 (en) * 2009-02-05 2016-05-12 Takeda Pharmaceutical Company Limited Pyridazinone compounds
US9187455B2 (en) * 2009-02-23 2015-11-17 Hoffmann-La Roche Inc. Substituted pyridazines as PDE10A inhibitors
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
JP5785548B2 (ja) * 2010-08-04 2015-09-30 武田薬品工業株式会社 縮合複素環化合物
JP5800814B2 (ja) * 2010-08-10 2015-10-28 武田薬品工業株式会社 複素環化合物およびその用途

Also Published As

Publication number Publication date
JP2012516890A (ja) 2012-07-26
JO3114B1 (ar) 2017-09-20
US8513251B2 (en) 2013-08-20
EA020690B1 (ru) 2015-01-30
ME02337B (me) 2016-06-20
US20120277430A1 (en) 2012-11-01
CN102365020A (zh) 2012-02-29
SG173175A1 (en) 2011-09-29
US8916566B2 (en) 2014-12-23
MY170610A (en) 2019-08-20
TN2011000362A1 (en) 2013-03-27
HUE027478T2 (en) 2016-09-28
US20120277431A1 (en) 2012-11-01
ECSP11011305A (es) 2011-11-30
CA2751565A1 (en) 2010-08-12
AU2010211050A1 (en) 2011-09-08
PL2393360T3 (pl) 2016-04-29
US20100197651A1 (en) 2010-08-05
HK1164642A1 (zh) 2012-09-28
GEP20146004B (en) 2014-01-10
SMT201600008B (it) 2016-02-25
ZA201106074B (en) 2012-10-31
US20120028951A1 (en) 2012-02-02
WO2010090737A1 (en) 2010-08-12
US20120277204A1 (en) 2012-11-01
TW201036958A (en) 2010-10-16
AU2010211050A2 (en) 2011-10-06
CA2751565C (en) 2017-05-16
PE20110991A1 (es) 2012-02-06
US8435995B2 (en) 2013-05-07
AR075238A1 (es) 2011-03-16
NZ594851A (en) 2013-10-25
RS54504B1 (en) 2016-06-30
EP2393360B1 (en) 2015-11-04
KR101730665B1 (ko) 2017-04-26
EA201171004A1 (ru) 2012-03-30
BRPI1008498B1 (pt) 2020-02-11
US8354411B2 (en) 2013-01-15
EP2393360A1 (en) 2011-12-14
CR20110440A (es) 2012-02-13
CO6410258A2 (es) 2012-03-30
EP2393360A4 (en) 2012-08-15
MX2011008305A (es) 2012-08-15
SI2393360T1 (sl) 2016-02-29
IL214137A (en) 2015-07-30
KR20110120931A (ko) 2011-11-04
US8778944B2 (en) 2014-07-15
US20170114044A1 (en) 2017-04-27
MA33072B1 (fr) 2012-02-01
CN102365020B (zh) 2014-07-30
ES2561181T3 (es) 2016-02-24
JP5659166B2 (ja) 2015-01-28
BRPI1008498A2 (pt) 2015-08-25
AU2010211050B2 (en) 2016-05-12
TWI457333B (zh) 2014-10-21
IL214137A0 (en) 2011-08-31
US20150099757A1 (en) 2015-04-09
HRP20160065T1 (hr) 2016-02-12
DOP2011000254A (es) 2011-09-30
EP3006031A1 (en) 2016-04-13
BRPI1008498B8 (pt) 2021-05-25
DK2393360T3 (en) 2016-02-01
US9550756B2 (en) 2017-01-24

Similar Documents

Publication Publication Date Title
UY32417A (es) Compuestos de piridazinona
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
CR20130024A (es) Compuestos heterocíclicos fusionados
AR099376A1 (es) Compuestos de diaminopirimidilo sustituidos, sus composiciones y métodos de tratamiento con aquellos
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
NI200900164A (es) COMPUESTOS AMINO- 5 -[ -4- (DIFLUOROMETOXI) FENIL SUSTITUIDO] -5- FENILIMIDAZOLONA COMO INHIBIDORES DE Beta - SECRETASA.
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
PE20151509A1 (es) Derivado de piridina monociclico
UY33701A (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
EP2602254A4 (en) HETEROCYCLIC COMPOUND
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
BR112016023299A8 (pt) composto tricíclico e inibidor de jak, agente preventivo, terapêutico ou de melhoria para doenças contra as quais inibição de jak é eficaz e para artrite reumatoide, medicamento e utilização desses compostos
CO6680697A2 (es) Compuestos heterociclicos para tratar o prevenir transtornos causado por neurotransmisión reducida de serotonina, norepinefrina o dopamina
MX2009005249A (es) Compuestos organicos.
WO2014128228A3 (de) Medikament
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.
AR089837A1 (es) Derivado de paroxetina
UA106741C2 (uk) Піридазинони
CY1117198T1 (el) Ενωσεις πυριδαζινονης
TH162570A (th) สารประกอบไพริดาซิโนน

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181211